Nxera Pharma Co., Ltd. announced it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals under their research collaboration. The payments follow Centessa's initiation of clinical development for ORX142, its second novel orexin receptor 2 (OX2R) agonist, after the FDA cleared an Investigational New Drug (IND) application for a Phase 1 study in healthy volunteers.
ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed by Centessa for the treatment of select neurological and neurodegenerative disorders.
Of the milestone receipt, US$1.8 million associated with the clearance of the IND will be recognized as revenue in the second quarter of 2025, and US$3.0 million associated with the initiation of clinical development will be recognized as revenue in the third quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.